Abstracts:
68. Mycology
Friday, October 22, 2010: 12:30 PM-2:00 PM

Target Audience: Academicians

Topical Category: M. Mycology including clinical and basic studies of fungal infections

Tracks: Adult ID, HIV, Investigative ID

CME Credits:

ACPE Credits:

ACPE Number:



Presentations:

609
Decreasing Time to Effective Management of Candidemia Using An Antimicrobial Stewardship Program (ASP) Approach
Erica E. Reed, PharmD; Ellen Keating, PharmD, MS; Karri A. Bauer, PharmD; Jessica West, MSPH; Preeti Pancholi, PhD; Joan-Miquel Balada-Llasat, PharmD, PhD; Julie E. Mangino, MD; Debra A. Goff, PharmD

610
Evaluation of a Positive Yeast-in-Blood Service
Kayla R. Stover, Pharm.D.; Rathel Nolan III, MD; John Cleary, Pharm.D.

611
Utility of b-Glucan and Galactomannan Assays in the Diagnosis of Fungal Diseases in Severe Burn Patients
Dana M. Blyth, M.D.; Duane R. Hospenthal, MD; Kevin K. Chung, MD; Leopoldo C. Cancio, MD; Booker T. King, MD; Clinton Murray, MD, FIDSA

612
Serum Galactomannan Testing in Patients On Highly-Active Mold Prophylaxis
Eric Cober, MD; Daniel Kaul, MD; Jeannina Smith, MD

613
Serum and Bronchoalveolar Lavage Fluid (BAL) Galactomannan (GM) Assays in Patients with Pulmonary Aspergilloma (PA)
Seong Yeon Park, MD; Song Mi Moon, MD; Ki-Ho Park, MD; Oh-Hyun Cho, MD; Yong Pil Chong, MD; Sang-Ho Choi, MD; June Hee Woo, MD; Yang Soo Kim, MD; Sung-Han Kim, MD

614
Hospital Database Analysis of Hematologic Malignancy and Bone Marrow Transplant/Stem Cell Transplant (BMT/SCT) Patients with Invasive Aspergillosis (IA)
Jennifer Stephens, PharmD; Xin Gao, PhD; Xiang Ji, MS; John Baddley, MD; Haran Schlamm, MD; Miriam Tarallo, MS

615
Detection of Aspergillus Spp. in Human Tissues Samples by Immunohistochemistry and in Situ Hybridization
Aniket Vadnerkar, MD; Cornelius Clancy, MD; Samuel Yousem; Sanja Dacic; Minh-Hong Nguyen, MD


617
Invasive Mold Infections in Patients with Solid Tumors
Iba Al Wohoush, MD; Coralia Mihu, M.D.; Dimitrios Kontoyiannis, MD, FIDSA; Ying Jiang, MS; Ray Hachem, MD; Kenneth V. I. Rolston, M.D.; Issam Raad, MD

618
Invasive Fungal Infections Following Combat-Related Injury
Kristopher Paolino, MD; James A. Henry, MD; Duane R. Hospenthal, MD; Glenn Wortmann, MD; Joshua Hartzell, MD

619
Invasive Mold Infections (IMIs) in Pediatric Cancer Patients (pts): a Single-Institution, 10 Year Retrospective Study
Georgios Pongas, MD; Russell Lewis, PharmD; Dimitrios Kontoyiannis, MD, FIDSA

620
Yeasts Fungemia in Kyoto University Hospital, Japan: The Impact of Non- Candida Yeasts
Masaki Yamamoto, MD; Shunji Takakura, MD, PhD; Akiko Uehara, MD; Keiko Yasuma, MD; Keisuke Yoshimoto, MD; Yasufumi Matsumura, MD; Aki Matsushima, MD, PhD; Miki Nagao, MD, PhD; Yutaka Ito, MD, PhD; Satoshi Ichiyama, MD, PhD

621
Invasive Aspergillosis (IA) in the “Low-Risk” Host: Epidemiology & Risk Factors
Jose A. Vazquez Jr., MD; Maria Tovar-Torres, MD; Ameet Hingwe, MD; Faiqa Cheema, MD; Ahmad Zawawi, MD; Verna L. Welch, Ph.D., MPH; Kimbal Ford, Pharm.D.

622
Outbreak of Aspergillus fumigatus at a Hospital Undergoing Major Construction — Arizona 2010
Monika Roy, MD; Steven Baty, DVM; Aarikha D'Souza, MPH; Tammy Sylvester, RN; Kristen Korte, RN, CIC; Tammy Beahm, RN, BSN, CIC; Kari Bjornard, BS; Eszter Deak, PhD; Kizee Etienne, MPH; Tara Waybrant, MS; Rebecca Sunenshine, MD; Ken Komatsu, MPH; S. Arunmozhi Balajee, PhD; Tom Chiller, MD, MSTMH

624
Invasive Aspergillus Infections (IA) in Patients with Chronic Lung Disease (CLD)
Roger Luo, Ph.D; Mireya Wessolossky; Verna L. Welch, Ph.D., MPH; Ajanta Sen, DO; Tara Babu, MD; David Luke, PharmD

625
Central Nervous System Blastomycosis in North Central Wisconsin
Subhashis Mitra, MD; Papia Kar, MD; Matthew C. Hall, MD

626
Epidemiology of Candidemia and Factors Associated with Candidemia Caused by Non-Albicans Candida Species: An 8-Year Experience of a Thai University Hospital
Sasisopin Kiertiburanakul, MD, MHS; Wootthisak Areewattananon, MD; Piriyaporn Chongtrakool, PhD; Yuda Sutherasan, MD; Siriorn P. Watcharananan, MD

627
Decline in Neonatal and Pediatric Candidemia – Preliminary Results From Population-Based Active Surveillance 2008-2010
Monika Roy, MD; Angela Ahlquist, MPH; Monica Farley, MD; Lee Harrison, MD; Wendy Baughman, MSPH; Betsy Siegel, RN, BSN; Rosemary Hollick, MD; Shawn Lockhart, PhD; Tom Chiller, MD, MSTMH; Benjamin J. Park, MD


629
Study of Candidemia Outcomes and Risk Factors in Critically Ill – A Retrospective Evaluation SCORE Study
Aarthi Narasimhan, MD; Nishchal Kumar, MD; Ali Rashidian, MD; Narinder Gill, MD; Naiel Nassar, MD; Vijay P. Balasubramanian, MD

630
The Use of Statins and Clinical Outcomes of Blood Stream Infection Due to Candida Species
Meredith L. Welch, MD; Angelike P. Liappis, MD; Virginia L. Kan, MD

631
Candidal Vs. Bacterial Severe Sepsis in the ICU: The Number-Needed-to-Treat (NNT)
Yoav Golan, MD, MS; Scott Micek, Pharm, D; Marin Kollef, MD

632
Pattern of Candidemia Therapy Modification From Treatment Onset: An Evaluation of Daily Changes by Regimen and Species
Daniel H. Kett, MD; Marcela A. Ferrada, M.D.; Andrew A. Quartin, M.D., M.P.H.; Michele Morris, MD, FIDSA


634
Incidence and Predictors of Ocular Candidiasis After Fungemia
Ayesha Khalid, MD; Albert Eid, MD; Lisa Clough, MD




638
Epidemiology and Risk Factors for Fluconazole Resistant Oral Yeasts in the Era of Antiretroviral Therapy (ART)
Payal K. Patel; Josh E. Erlandsen; William R. Kirkpatrick; George R. Thompson III, MD; Monica L. Herrera; Deborah K. Berg; Steven D. Westbrook; Brian L. Wickes; Nathan P. Wiederhold; Spencer W. Redding; Thomas F. Patterson, MD

640
Pulmonary Immunology of Human Coccidioidomycosis
Neil Ampel, MD, FIDSA; Lance A. Nesbit, B.S.; Kenneth S. Knox, M.D.

641
Lessons From the Cryptococcus Outbreak in the Pacific Northwest: Emergence, Expansion, and Virulence Attributes of Highly Virulent C. gattii Genotypes
Edmond J. Byrnes III, B.S.; Wenjun Li, M.D., Ph.D.; Yonathan Lewit, B.S.; Kerstin Voelz; Hansong Ma; Ping Ren, Ph.D.; Kieren A. Marr, M.D.; Dee A. Carter, Ph.D.; Vishnu Chaturvedi, Ph.D.; Robert J. Bildfell, DVM; Robin C. May, Ph.D.; Joseph Heitman, MD, PhD

642
Public Health Surveillance for Cryptococcus Gattii: An Emerging Disease in the United States Pacific Northwest
Julie Harris, PhD, MPH; Shawn Lockhart, PhD; Nicola Marsden-Haug, MPH; Ron Wohrle, DVM; Cyndi Free; Emilio DeBess, DVM; Tom Chiller, MD, MSTMH

643
Multi-Locus Sequence Typing of Coastal Pacific Northwest Cryptococcus Isolates
Min-Kuang Lee, MS; Stephanie Man, BS; Andrew Balbirnie, BS; Sultana Mithani, BS; Quantine Wong, BS; Deema Al-Okaily, MD; Linda MN Hoang, MD, FRCPC; Muhammad G. Morshed, PhD

644
Evaluation of a Multiplex PCR for Typing of Cryptococcus Spp
Andrew Balbirnie, BS; Danielle Jorgensen, BS; Loretta Janz, BS; Min-Kuang Lee, MS; Sultana Mithani, BS; Muhammad G. Morshed, PhD; Linda MN Hoang, MD, FRCPC

645
Cryptococcus gattii Infections in Non-Immunocompromised Patients in the Northern Territory of Australia
Krispin M. Hajkowicz, MBBS, FRACP; Allen C. Cheng, MBBS, FRACP, MPH, PhD; Bart J. Currie, FRACP

646
Mechanisms of Azole Resistance in Cryptococcus gattii
Luiz R. Basso Jr., PhD; Charles Gast, BA; Brian Wong, MD

647
Cryptococcosis Among HIV-Negative, Non-Solid Organ Transplant Patients at Duke University Medical Center (DUMC): 1996-2009
Emily W. Bratton, MSPH; Nada El Husseini, MD; Cody A. Chastain, MD; Michael S. Lee, MD; John Perfect, MD, FIDSA


649
Assessment of Adherence to IDSA Guidelines for Management of Cryptococcal Meningitis (CM): Does It Affect Outcome?
Mariejane Braza, MD; John R. Graybill, MD; Thomas F. Patterson, MD; Elizabeth Walter, MD

650
Molecular Characteristics of Cryptococcus Isolates From Marine Mammals Stranded along the Pacific Northwest Coast
Min-Kuang Lee, MS; Stephanie Man, BS; Andrew Balbimie, BS; Sultana Mithani, BS; Quantine Wong, BS; Erin Zabek, BS; Stephen Raverty, DVM, MS, PhD; Linda MN Hoang, MD, FRCPC; Muhammad G. Morshed, PhD

651
A Single-Center Ten Year Retrospective Analysis of Fusarium Infection in Patients with Malignancy
Moise L. Carrington, MD; Aliyah Baluch, MD; Ana Velez, MD; John Greene, MD

652
Kodamaea Ohmeri Fungemia Is Not An Uncommon Entity in India: Need for a Systematic Study
Arunaloke Chakrabarti, MD; Mandya R. Shivaprakash, MD; Pratibha Kale, MBBS; Prakash Hariprasath, MSc; Manpreet Dhaliwal, MSc; Mohammed A. Zameer, MS; Sunit Singhi, MD; Katragadda LN Rao, MCh

653
Risk Factors for Pneumocystis jirovecii Pneumonia (PCP) in Patients with Hematologic Malignancies (HM)
Karam Obeid, MD; Javier Aguilar, M.D.; Susan Szpunar, PhD; Ayad al-Katib, M.D.; Mamta Sharma, MD; Ramon Delbusto, M.D.; Leonard Johnson, MD

654
Diagnostic Yield of S-Adenosylmethionine and 1-->3 β-D-Glucan Serum Levels and Correlation with Clinical Parameters in Non-HIV+ Immunocompromised Patients with Pneumocystis Pneumonia
Mark G.J. de Boer, M.D.; Luc B.S. Gelinck, M.D., PhD; Bertrand D. van Zelst; Wendy W.J. van de Sande, PhD; Robert de Jonge, PhD; Frank P. Kroon, M.D., PhD

655
Therapeutic Strategy for Trichosporon Fungemia in Patients with Acute Leukemia: Clinical Evaluation of Seven Cases Who Recovered From This Infection
Kazunori Nakase, Ph.D., MD.; K. Suzuki, MD.; T. Kyo, MD.; T. Kohara, M.T.; Y. Sugawara, M.D.; T. Shibazaki, Ph.D., M.D.; T. Tsukada, Ph.D., M.D.; S. Kageyama, Ph.D., M.D.; N. Katayama, Ph.D., M.D.


657
Single Agent Versus Multiple Agent Antifungal Therapy in Fusarium Infection: Ten Year Experience in a Neutropenic Patient Population
Rebecca L. Tombleson, PharmD; Deepti S. Canchi, MD; John Greene, MD; Rod E. Quilitz, PharmD

658
Serum Concentrations and Tolerability of Standard and Weight-Based Oral Dosing Regimens of Voriconazole
Jason E. Bowling, MD; James S. Lewis II, PharmD; Thomas F. Patterson, MD


660
Early Treatment with Fluconazole May Abrogate the Development of IgG Antibodies in Coccidioidomycosis
George R. Thompson III, MD; Suzanne M. Johnson, PhD; Stuart H. Cohen, MD, FIDSA; Demosthenes Pappagianis, MD, PhD

661
Use of Cimetidine to Increase Voriconazole Concentrations in a Patient with Suboptimal Voriconazole Exposure
Timothy J. Jancel, PharmD; Scott Penzak, PharmD; Alexandra F. Freeman, MD; Steven Holland, MD

662
Voriconazole-Associated Severe Hyponatremia
Kye-Hyung Kim, MD; Pyoeng Gyun Choe, MD; Jin-su Song, MD; Jinyong Park, MD; Nak-Hyun Kim, MD; Jongyoun Yi, MD; Kyoung-Ho Song, MD; Sang-Won Park, MD, PhD; Hong Bin Kim, MD, PhD; Nam Joong Kim, MD, PhD; Wan Beom Park, MD, PhD; Myoung-don Oh, MD, PhD

663
Oral Antifungal Prophylaxis in Patients with Squamous Cell Cancer of the Head and Neck Undergoing Radiotherapy and Its Effect On Oral Candida Colonization
Helmut J.F. Salzer, MD; Robert Krause, MD; Sabine Reinisch, MD; Harald Kessler, MD; Karin S. Kapp; Brigitte Santner, MD; Richard Partl, MD; Reinhard B. Raggam, MD



666
Utilization Patterns of Caspofungin and Micafungin for Treating Invasive Fungal Infections
Connie Parks; Ritesh Kumar, Ph.D.; Girish D. Prajapati, M.B.B.S., MPH; Blane Schilling, MD


668
In Vitro Evaluation of the Antifungal Activity of NVC-422 (N,N-dichloro-2,2-dimethyltaurine) Using a Novel Cadaver Nail Model
Sarah A. Ibrahim, PhD; Dmitri Debabov, PhD; Mahmoud Ghannoum, PhD; Mark Anderson, PhD; Bahram Memarzadeh, PhD

669
A Comparative Evaluation of Combination Therapy of Fluconazole 1% and Urea 40% Compared with Fluconazole 1% Alone in a Nail Lacquer for Treatment of Onychomycosis: Therapeutic Trial
Shahindokht Bassiri-Jahromi; Amir Hooshang Ehsani, MD; Mostafa Mirshams Shahshahani, MD; Behrooz Jamshidi, PharmD; Aref Amirkhani, PhD
See more of: Abstracts

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 21 with the exception of research findings presented at IDSA press conferences.

 
 
   
 

© Copyright IDSA 2009 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org